243 related articles for article (PubMed ID: 15283897)
1. The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise.
Andriole GL; Reding D; Hayes RB; Prorok PC; Gohagan JK;
Urol Oncol; 2004; 22(4):358-61. PubMed ID: 15283897
[TBL] [Abstract][Full Text] [Related]
2. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
3. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
4. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial.
Pinsky PF; Miller A; Kramer BS; Church T; Reding D; Prorok P; Gelmann E; Schoen RE; Buys S; Hayes RB; Berg CD
Am J Epidemiol; 2007 Apr; 165(8):874-81. PubMed ID: 17244633
[TBL] [Abstract][Full Text] [Related]
5. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
6. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
[TBL] [Abstract][Full Text] [Related]
7. [Screening for cancer: what's new?].
Sasco AJ
Bull Cancer; 2000 Mar; 87(3):239-43. PubMed ID: 10779811
[TBL] [Abstract][Full Text] [Related]
8. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Andriole GL
Recent Results Cancer Res; 2014; 202():53-7. PubMed ID: 24531777
[TBL] [Abstract][Full Text] [Related]
9. The economic impact of false-positive cancer screens.
Lafata JE; Simpkins J; Lamerato L; Poisson L; Divine G; Johnson CC
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2126-32. PubMed ID: 15598770
[TBL] [Abstract][Full Text] [Related]
10. Lung cancer screening gets risk-specific.
Peres J
J Natl Cancer Inst; 2013 Jan; 105(1):1-2. PubMed ID: 23257155
[No Abstract] [Full Text] [Related]
11. Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial.
Grubb RL; Pinsky P; Prorok PC; Andriole GL
Eur Urol; 2015 Oct; 68(4):545-6. PubMed ID: 25959167
[TBL] [Abstract][Full Text] [Related]
12. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
14. [Tumor screening with special reference to breast and prostate carcinoma].
Jost LM
Ther Umsch; 1997 Aug; 54(8):439-50. PubMed ID: 9381414
[TBL] [Abstract][Full Text] [Related]
15. Behavioral associations between prostate and colon cancer screening.
Carlos RC; Underwood W; Fendrick AM; Bernstein SJ
J Am Coll Surg; 2005 Feb; 200(2):216-23. PubMed ID: 15664097
[TBL] [Abstract][Full Text] [Related]
16. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Miller AB; Yurgalevitch S; Weissfeld JL;
Control Clin Trials; 2000 Dec; 21(6 Suppl):400S-406S. PubMed ID: 11189691
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.
Aus G; Bergdahl S; Lodding P; Lilja H; Hugosson J
Eur Urol; 2007 Mar; 51(3):659-64. PubMed ID: 16934392
[TBL] [Abstract][Full Text] [Related]
18. Breast, colon, and prostate screening in the adult population of Croatia: does rural origin matter?
Polasek O; Kolcic I; Voncina L; Strnad M; Vuletic S; Kern J
Rural Remote Health; 2007; 7(3):749. PubMed ID: 17900222
[TBL] [Abstract][Full Text] [Related]
19. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.
van der Cruijsen-Koeter IW; Vis AN; Roobol MJ; Wildhagen MF; de Koning HJ; van der Kwast TH; Schröder FH
J Urol; 2005 Jul; 174(1):121-5. PubMed ID: 15947595
[TBL] [Abstract][Full Text] [Related]
20. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing.
Oberaigner W; Horninger W; Klocker H; Schönitzer D; Stühlinger W; Bartsch G
Am J Epidemiol; 2006 Aug; 164(4):376-84. PubMed ID: 16829552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
